Essential biopharma news and analysis

Independent journalism since 2016

Full articles inside the email — read the news on your terms. Uncluttered design. Sharp writing. And it's absolutely free, or you can pay to get Endpoints News without the email advertising. Corporate subscriptions are one simple price, regardless of size. With Endpoints, you'll never miss an important drug development story again.

Subscribe to Endpoints News

About You


ENDPOINTS by John Carroll & team — all the news at 11:30a ET

EARLY EDITIONby Arsalan Arif — our skimmable digest at 7:15a ET

Endpoints News is an independent journalism company. Readers fund our growth with premium subscriptions, ensuring our long-term viability. Advertising from trusted partners screened by Endpoints guarantees access for all to quality journalism. Here's our privacy policy.